Hem › Kronisk lymfatisk leukemi › Washington
Kliniska studier för Kronisk lymfatisk leukemi i Washington
26 studier för Kronisk lymfatisk leukemi söker deltagare vid platser i Washington.
Städer i Washington
Officiell studietext (engelska)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Providence Regional Cancer System-Aberdeen, Aberdeen
- PeaceHealth Saint Joseph Medical Center, Bellingham
- Providence Regional Cancer System-Centralia, Centralia
- och 19 fler
RekryterarObservationsstudieFriska volontärer välkomna
Ålder 40 till 75 · Alla kön · Uppdaterad 2 okt. 2026 · NCT05334069A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Study Site 103, Tacoma
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 1 okt. 2026 · NCT07582432A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, Seattle
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 30 sep. 2026 · NCT06542250Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- FHCC Overlake, Bellevue
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Cancer Institute-Issaquah, Issaquah
- och 7 fler
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 30 sep. 2026 · NCT04269902A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Swedish Medical Center Swedish Cancer Institute First Hill Campus, Seattle
- Northwest Cancer Specialist, Pc(Us Oncology Research), Vancouver
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 28 sep. 2026 · NCT06943872A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Fred Hutchinson Cancer Research Center, Seattle
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 28 sep. 2026 · NCT05006716A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Fred Hutchinson Cancer Research Center, Seattle
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 28 sep. 2026 · NCT07277231A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Fred Hutchinson Cancer Research Center, Seattle
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 28 sep. 2026 · NCT06697184A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Fred Hutchinson Cancer Research Center, Seattle
- Summit Cancer Centers, Spokane
- Northwest Medical Specialties, Tacoma
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 28 sep. 2026 · NCT06973187A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Vista Oncology ( Site 5449), Olympia
- Medical Oncology Associates, PS ( Site 5406), Spokane
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 24 sep. 2026 · NCT05947851A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Medical Oncology Associates, PS (dba Summit Cancer Centers) ( Site 0010), Spokane
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 24 sep. 2026 · NCT06136559Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Fred Hutchinson Cancer Research Center, Seattle
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 21 sep. 2026 · NCT07648264A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Fred Hutchinson Cancer Center, Seattle
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 17 sep. 2026 · NCT07221500Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 11 sep. 2026 · NCT07194980A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Medical Oncology Associates, PS, Spokane
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 17 aug. 2026 · NCT05254743A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- Fred Hutch Cancer Center, Seattle
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 17 aug. 2026 · NCT06528301ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
- Medical Oncology Associates - Spokane, Spokane
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 11 aug. 2026 · NCT07342478Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RekryterarFas 2Friska volontärer välkomna
6 Months · Alla kön · Uppdaterad 29 maj 2026 · NCT04195633Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 18 maj 2026 · NCT04941716Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 22 apr. 2026 · NCT06839053A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Vista Oncology - East Olympia /ID# 267337, Olympia
- Northwest Medical Specialties Tacoma /ID# 266327, Tacoma
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 9 apr. 2026 · NCT06428019A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Swedish Cancer Institute, Seattle
RekryterarFas 4
Ålder 18 och äldre · Alla kön · Uppdaterad 2 mars 2026 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Swedish Cancer Institute, Seattle
RekryterarFas 4
Ålder 18 och äldre · Alla kön · Uppdaterad 2 mars 2026 · NCT06876649Study of SGR-1505 in Mature B-Cell Neoplasms
- Fred Hutchinson Cancer Center, Seattle
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 13 feb. 2026 · NCT05544019A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
RekryterarFas 2
Ålder 18 till 80 · Alla kön · Uppdaterad 14 okt. 2025 · NCT06520098A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Swedish Cancer Institute, Seattle
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 2 okt. 2025 · NCT05780034Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.